Innovation in AMR - the CARB-X Perspective.
ACS infectious diseases(2020)
摘要
The spread of drug-resistant bacterial pathogens has been recognized as one of the largest global threats to mankind. In order to continue to benefit from the advancement of modern medicine, new treatment, prevention and diagnostic products are needed to satisfactorily treat or prevent infections. CARB-X is a global non-profit public-private partnership dedicated to accelerating antibacterial-related research to tackle the rising threat of drug-resistant bacteria. The CARB-X portfolio is the world's largest early development pipeline of new antibiotics, vaccines, rapid diagnostics and other products to prevent, diagnose and treat life-threatening bacterial infections. Since inception, three application rounds of funding have been completed with a significant worldwide response.
更多查看译文
关键词
antibacterial,resistance,CARB-X,funding,research and development,therapeutics,vaccines,diagnostics,preclinical
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要